Bone Mineral Density (BMD) in HIV Infection

• BMD (baseline, and at 2 years) according to:
• - calcium intake, physical activity,
• - CD4 lymphocyte count, HIV viral load,
• - bone metabolism biological markers (osteocalcine, C telopeptide collagen type I in urine),
• - leptine, parathormone, 25 OH D3

Osteopenia and osteoporosis are increasingly reported in HIV-infected patients, and appear to be more frequent than in general population. However, pathogenesis remains unclear, and published studies still give non concordant results.

We therefore started a prospective study, to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis. BMD evolution over a 2-years period of follow-up, will be compared between patients starting ARV therapy, and subjects without HAART (no indication of treatment). A correlation between BMD and several factors will be looked at (see below).

This study with individual direct benefice, is conducted in 3 outpatients clinics (Strasbourg, Colmar, Mulhouse) in collaboration with the rheumatologic teams. 60 patients are planned to be included over a 3-years inclusion period

• Osteopenia
• Osteoporosis

Inclusion Criteria:

• HIV-1 infected men, Caucasian, age > 18 years, ARV-naïve

Exclusion Criteria:

• HIV-infected women, subjects < 18 years, non-Caucasian men, ARV-experienced patients, subjects not able or willing to give informed consent, endocrine disease or treatment which could affect bone metabolism